Status:
TERMINATED
Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With or Without Stoma
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The goal is to evaluate whether the renunciation of a diverting stoma in patients with adjuvant chemotherapy after low anterior resection with total mesorectal excision (TME) and neoadjuvant chemoradi...
Detailed Description
In most cases it is recommended that patients after low anterior resection with TME and neoadjuvant chemoradiotherapy for rectal cancer need a temporarily diverting stoma. Recent evidence suggests tha...
Eligibility Criteria
Inclusion
- age older than 18,
- low anterior resection and TME due to rectum carcinoma after standardized neoadjuvant combined chemo- and radiotherapy and receiving adjuvant postoperative chemotherapy,
- German speaking patient who is capable to fill in the questionnaire,
- signed informed consent
Exclusion
- age younger than 18,
- preoperative stoma,
- not German speaking
- inability to fill in the questionnaire,
- no standardized chemo- and radiotherapy
Key Trial Info
Start Date :
March 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 22 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03487484
Start Date
March 22 2018
End Date
March 22 2020
Last Update
April 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Claraspital
Basel, Switzerland, 4058